Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2026)

Rani Therapeutics Holdings has reported Common Equity for 7 years, with the latest figure at $48.0 million in Q2 2026.

• On a quarterly basis, Common Equity rose 624.25% year-over-year to $48.0 million in Q2 2026; TTM through Jun 2026 was $48.0 million, a 624.25% increase from a year earlier, with the FY2025 full-year figure at $41.5 million, up 1088.43% from the prior year.
• Common Equity was $48.0 million for Q2 2026 at Rani Therapeutics Holdings, up from $35.5 million in the prior quarter.
• The five-year high for Common Equity was $110.6 million in Q1 2022, with the low at -$12.0 million in Q3 2025.
• Average Common Equity over 5 years is $37.1 million, with a median of $35.2 million recorded in 2023.
• The largest YoY upside for Common Equity was 1088.43% in 2025 against a maximum downside of 307.32% in 2025.
• Over 5 years, Common Equity stood at $74.0 million in 2022, then plunged by 65.62% to $25.4 million in 2023, then sank by 86.27% to $3.5 million in 2024, then jumped by 1088.43% to $41.5 million in 2025, then gained by 15.59% to $48.0 million in 2026.
• The last three Common Equity figures came in at $48.0 million (Q2 2026), $35.5 million (Q1 2026), and $41.5 million (Q4 2025), per Business Quant data.